A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Kiniksa Pharmaceuticals International, plc
KNSA
$6.0B
Mkt Cap
$76.48
-2.60%
Business description not available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 754M | 678M | 423M | 270M | 220M | - |
| Net Income | 73M | 59M | -43M | 14M | 183M | -158M |
| EPS | $0.92 | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
| Free Cash Flow | 164M | 136M | 25M | 13M | 5.7M | -127M |
| ROIC | 46.7% | 28.7% | -9.8% | 3.4% | 63.1% | -63.6% |
| Gross Margin | - | 56.6% | 57.9% | 70.8% | 89.6% | - |
| Debt/Equity | 0.00 | 0.02 | 0.02 | 0.03 | 0.01 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 93M | 77M | -46M | -25M | 9.8M | -157M |
| Operating Margin | 12.4% | 11.4% | -10.8% | -9.3% | 4.4% | - |
| ROE | 12.1% | 11.7% | -9.8% | 3.4% | 63.1% | -63.6% |
| Shares Outstanding | 82M | 79M | 72M | 70M | 71M | 69M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | 220M | 270M | 423M | 678M | 754M |
| Gross Margin | N/A | 89.6% | 70.8% | 57.9% | 56.6% | N/A |
| R&D | 99M | 65M | 76M | 112M | 97M | 105M |
| SG&A | 86M | 98M | 129M | 168M | 196M | 214M |
| EBIT | -157M | 9.8M | -25M | -46M | 77M | 93M |
| Op. Margin | N/A | 4.4% | -9.3% | -10.8% | 11.4% | 12.4% |
| Net Income | -158M | 183M | 14M | -43M | 59M | 73M |
| Net Margin | N/A | 83.3% | 5.2% | -10.2% | 8.7% | 9.7% |
| Non-Recurring | -103K | -33K | -179K | 24K | 120K | 120K |
| Returns on Capital | ||||||
| ROIC | -63.6% | 63.1% | 3.4% | -9.8% | 28.7% | 46.7% |
| ROE | -63.6% | 63.1% | 3.4% | -9.8% | 11.7% | 12.1% |
| ROA | -54.2% | 53.0% | 2.9% | -7.8% | 8.8% | 8.9% |
| Cash Flow | ||||||
| Op. Cash Flow | -126M | 5.8M | 13M | 26M | 138M | 166M |
| Free Cash Flow | -127M | 5.7M | 13M | 25M | 136M | 164M |
| Owner Earnings | -157M | -26M | -16M | -6.7M | 99M | 120M |
| CapEx | 415K | 105K | 130K | 277K | 1.6M | 1.6M |
| Maint. CapEx | 5.9M | 6.9M | 2.3M | 1.7M | 1.6M | 6.8M |
| Growth CapEx | 0 | 0 | 0 | 0 | 14K | 0 |
| D&A | 5.9M | 6.9M | 2.3M | 1.7M | 1.6M | 6.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 1.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 25M | 25M | 27M | 31M | 37M | 39M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -176M | -185M | -194M | -234M | -405M | -468M |
| Cash & Equiv. | 122M | 123M | 108M | 184M | 166M | 468M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.03 | 0.01 | 0.03 | 0.02 | 0.02 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 185M | 396M | 439M | 438M | 568M | 606M |
| Total Assets | 233M | 460M | 526M | 581M | 764M | 825M |
| Total Liabilities | 48M | 64M | 87M | 142M | 196M | 220M |
| Intangibles | 19M | 18M | 17M | 16M | 15M | 15M |
| Retained Earnings | -675M | -492M | -478M | -521M | -462M | -440M |
| Working Capital | 152M | 196M | 213M | 231M | 388M | 438M |
| Current Assets | 196M | 243M | 276M | 332M | 527M | 594M |
| Current Liabilities | 45M | 47M | 64M | 101M | 139M | 157M |
| Per Share Data | ||||||
| EPS | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 | 0.92 |
| Owner EPS | -2.29 | -0.37 | -0.23 | -0.09 | 1.26 | 1.45 |
| Book Value | 2.69 | 5.62 | 6.23 | 6.09 | 7.21 | 7.35 |
| Cash Flow/Share | -1.84 | 0.08 | 0.19 | 0.36 | 1.75 | 0.97 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 68.7M | 70.5M | 70.4M | 72.0M | 78.7M | 82.4M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 83.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 38.4 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 62.6 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 10.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 8.4 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | 2.6% |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 6.3B |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.48 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.48 |
Kiniksa Pharmaceuticals International, plc passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 4.3% with a gross margin of 68.7%.
Kiniksa Pharmaceuticals International, plc (KNSA) has a current P/E ratio of 83.0.
Kiniksa Pharmaceuticals International, plc (KNSA) has a 5-year average return on invested capital (ROIC) of 4.3%. This is below average and may indicate limited pricing power.
Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $6.3B. It is classified as a mid-cap stock.
Kiniksa Pharmaceuticals International, plc (KNSA) does not currently pay a regular dividend.
Kiniksa Pharmaceuticals International, plc (KNSA) reported annual revenue of $678 million in its most recent fiscal year, based on SEC EDGAR filings.
Kiniksa Pharmaceuticals International, plc (KNSA) has a net profit margin of 8.7%. This is a modest margin.
Kiniksa Pharmaceuticals International, plc (KNSA) generated $136 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Kiniksa Pharmaceuticals International, plc (KNSA) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Kiniksa Pharmaceuticals International, plc (KNSA) reported earnings per share (EPS) of $0.75 in its most recent fiscal year.
Kiniksa Pharmaceuticals International, plc (KNSA) has a return on equity (ROE) of 11.7%. This indicates moderate shareholder returns.
Kiniksa Pharmaceuticals International, plc (KNSA) has a 5-year average gross margin of 68.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Kiniksa Pharmaceuticals International, plc (KNSA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kiniksa Pharmaceuticals International, plc (KNSA) has a book value per share of $7.21, based on its most recent annual SEC filing.